Indication
High-risk Neuroblastoma
5 clinical trials
9 products
1 drug
Clinical trial
An Open-Label, Multi-Center, Single-Arm, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-Risk NeuroblastomaStatus: Completed, Estimated PCD: 2023-06-28
Product
Dinutuximab BetaProduct
13 cis Retinoic acidProduct
13-cis Retinoic AcidProduct
DinutuximabProduct
13 cis retinoic acidClinical trial
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
NaxitamabProduct
CeritinibClinical trial
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2026-03-21
Product
OPT-821Clinical trial
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy in Patients With High-Risk Neuroblastoma Receiving Tandem TransplantsStatus: Not yet recruiting, Estimated PCD: 2027-03-31
Product
DefibrotideClinical trial
Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-01-30
Product
GPC2 CAR T cells